Want to see GYRE full AI Analyst Report?
Total Valuation
Gyre Therapeutics has a market cap or net worth of $696.64M. The enterprise value is $648.81.
Market Cap$696.64M
Enterprise Value$648.81
Share Statistics
Gyre Therapeutics has 106,033,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding106,033,760
Owned by Insiders63.46%
Owned by Institutions4.45%
Financial Efficiency
Gyre Therapeutics’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 5.30%.
Return on Equity (ROE)0.05
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)5.30%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee186.54K
Profits Per Employee15.81K
Employee Count625
Asset Turnover0.70
Inventory Turnover0.53
Valuation Ratios
The current PE Ratio of Gyre Therapeutics is ―. Gyre Therapeutics’s PEG ratio is -2.10.
PE Ratio―
PS Ratio5.41
PB Ratio5.95
Price to Fair Value5.95
Price to FCF-3.50K
Price to Operating Cash Flow-44.91
PEG Ratio-2.10
Income Statement
In the last 12 months, Gyre Therapeutics had revenue of 116.59M and earned 5.03M in profits. Earnings per share was 0.06.
Revenue116.59M
Gross Profit111.17M
Operating Income11.49M
Pretax Income14.44M
Net Income5.03M
EBITDA16.96M
Earnings Per Share (EPS)0.06
Cash Flow
In the last 12 months, operating cash flow was -14.50M and capital expenditures -2.29M, giving a free cash flow of -16.79M billion.
Operating Cash Flow-14.50M
Free Cash Flow-16.79M
Free Cash Flow per Share-0.16
Dividends & Yields
Gyre Therapeutics pays an annual dividend of $3.6, resulting in a dividend yield of ―
Dividend Per Share$3.6
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.72
52-Week Price Change-19.93%
50-Day Moving Average6.46
200-Day Moving Average7.16
Relative Strength Index (RSI)47.48
Average Volume (3m)52.08K
Important Dates
Gyre Therapeutics upcoming earnings date is Nov 18, 2026, TBA (Confirmed).
Last Earnings DateAug 7, 2026
Next Earnings DateNov 18, 2026
Ex-Dividend Date―
Financial Position
Gyre Therapeutics as a current ratio of 5.60, with Debt / Equity ratio of 2.62%
Current Ratio5.60
Quick Ratio5.04
Debt to Market Cap0.00
Net Debt to EBITDA-2.13
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Gyre Therapeutics has paid 4.56M in taxes.
Income Tax4.56M
Effective Tax Rate0.32
Enterprise Valuation
Gyre Therapeutics EV to EBITDA ratio is 35.07, with an EV/FCF ratio of -3.30K.
EV to Sales5.10
EV to EBITDA35.07
EV to Free Cash Flow-3.30K
EV to Operating Cash Flow588.75
Balance Sheet
Gyre Therapeutics has $74.80M in cash and marketable securities with $3.42M in debt, giving a net cash position of $71.38M billion.
Cash & Marketable Securities$74.80M
Total Debt$3.42M
Net Cash$71.38M
Net Cash Per Share$0.67
Tangible Book Value Per Share$1.54
Margins
Gross margin is 94.30%, with operating margin of 9.86%, and net profit margin of 4.31%.
Gross Margin94.30%
Operating Margin9.86%
Pretax Margin12.38%
Net Profit Margin4.31%
EBITDA Margin14.54%
EBIT Margin12.38%
Analyst Forecast
The average price target for Gyre Therapeutics is $19.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$19.00
Price Target Upside185.71% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast16.83%
EPS Growth Forecast-494.61%